Cancer Family
Malignant Head and Neck Neoplasm
CI-CAN-00000236Explore in graph →
1,431 active trials17 approved drugs142 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000236Explore in graph →
Clinical trials
5,448 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (629)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04085900 | Screening Nasopharyngeal Carcinoma With EBV Associated Biomarkers in Zhongshan City | recruiting | — | 40,000 | Zhongshan People's Hospital, Guangdong, ChinaOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05877599 | A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | recruiting | Phase 1 | 45 | AstraZenecaINDUSTRY | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06309225 | Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly((DACHOC-E)) | recruiting | N/A | 20 | Omar MahmoudOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06479811 | [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers | recruiting | Phase 1 | 120 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT06589804 | Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | recruiting | Phase 3 | 158 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07195734 | Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer | recruiting | Phase 2 | 180 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma | recruiting | Phase 2 | 35 | City of Hope Medical CenterOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT07635420 | Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction (VISION Trial)(VISION) | recruiting | Phase 4 | 244 | Region SkaneOTHER | 1 | Sep 29, 2026 | clinicaltrials |
| NCT03702309 | Liquid Biopsy Evaluation and Repository Development at Princess Margaret(LIBERATE) | recruiting | — | 2,500 | University Health Network, TorontoOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04216732 | Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management | recruiting | — | 2,030 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT04858334 | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | recruiting | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 3 | Sep 25, 2026 | clinicaltrials |
| NCT05136196 | BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | recruiting | Phase 2 | 150 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06172478 | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 2 | 740 | Daiichi SankyoINDUSTRY | 16 | Sep 25, 2026 | clinicaltrials |
| NCT06385080 | A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer(OrigAMI-4) | recruiting | Phase 1 / Phase 2 | 287 | Janssen Research & Development, LLCINDUSTRY | 11 | Sep 25, 2026 | clinicaltrials |
| NCT06667427 | Pilot Study of Management of Facial Paralysis in the Oncologic Patient: Nerve Transfer Techniques to Improve Facial Function and Quality of Life | recruiting | N/A | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06980038 | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer | recruiting | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07124000 | DESTINY-PANTUMOUR04(DP-04) | recruiting | — | 100 | AstraZenecaINDUSTRY | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07142005 | Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer | recruiting | — | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07219212 | A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma(LUMIRAY) | recruiting | Phase 1 | 45 | Johnson & Johnson Enterprise Innovation Inc.INDUSTRY | 3 | Sep 25, 2026 | clinicaltrials |
| NCT07276399 | A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer(OrigAMI-5) | recruiting | Phase 3 | 500 | Janssen Research & Development, LLCINDUSTRY | 22 | Sep 25, 2026 | clinicaltrials |
| NCT05898789 | Virtual Rehabilitation for Cancer Survivors | recruiting | N/A | 388 | University Health Network, TorontoOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06475989 | Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer | recruiting | Phase 3 | 264 | ECOG-ACRIN Cancer Research GroupNETWORK | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06305676 | Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)(BASH OPC) | recruiting | — | 400 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03765333 | GETNE Registration of Thyroid Cancer | recruiting | — | 20 | Grupo Espanol de Tumores NeuroendocrinosOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT04671667 | Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05172245 | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | recruiting | Phase 1 | 46 | National Cancer Institute (NCI)NIH | 2 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07006727 | Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors | recruiting | Phase 1 | 116 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 22, 2026 | clinicaltrials |
| NCT07060261 | Pre-Op MRI on Margin Status for Transoral Robotic Surgery for HPV+ Tonsillar Squamous Cell Carcinoma | recruiting | N/A | 30 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07428057 | Postoperative Hypocalcemia After Thyroidectomy | recruiting | — | 600 | Minia UniversityOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT07565740 | Intranasal WSK-IM05 Vaccine Plus Tislelizumab as Neoadjuvant Therapy for HPV+ OPSCC | recruiting | Phase 1 | 9 | West China HospitalOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05983432 | Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | recruiting | Phase 1 | 540 | SystImmune Inc.INDUSTRY | 5 | Sep 21, 2026 | clinicaltrials |
| NCT06176989 | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06258811 | Neoadjuvant Immunochemotherapy for LAOSCC | recruiting | Phase 3 | 134 | Lai-ping ZhongOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06623266 | Neck Observation or Elective Neck Dissection in cT1N0M0 OSCC | recruiting | N/A | 300 | Huashan HospitalOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06736379 | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | recruiting | Phase 1 | 41 | VLP TherapeuticsINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06781567 | Clinical Trial of HG146 Administered to Participants With Adenoid Cystic Carcinoma(HG146) | recruiting | Phase 2 | 140 | HitGen Inc.INDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07162480 | Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Carcinoma Subtype I (ACC-I) | recruiting | Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT06161545 | Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma | recruiting | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06507878 | Global Real World Data in Patients With Advanced Thyroid Cancer on Standard of Care and Specialized Interventions- Registry of Oncologic Outcomes With Testing and Treatment.(GRASSROOT) | recruiting | — | 459 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07644585 | A Pilot Study of Ultra-High Dose Rate (ConformalFLASH®), for Reirradiation of Carcinoma of the Head and Neck(C-FLASH-01) | recruiting | N/A | 10 | IBA Proton Therapy, Inc.INDUSTRY | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05106608 | Photobiomodulation Therapy Plus M-health in Head and Neck Cancer Patients: LAXER Study(LAXER) | recruiting | N/A | 60 | Universidad de GranadaOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06607406 | Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery | recruiting | N/A | 75 | Wake Forest University Health SciencesOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06666881 | Skeletal Muscle Mass Changes on Images for Prediction of Prognosis After Exercise Training in HNSCC Patients | recruiting | N/A | 280 | Chang Gung Memorial HospitalOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | recruiting | Phase 1 | 150 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07172802 | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 102 | GI Innovation, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07177443 | Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal Carcinoma | recruiting | Phase 3 | 710 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Sep 17, 2026 | clinicaltrials |
Data updated 18 hours agoSource updated Sep 29, 2026source: clinicaltrials